Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomised, double-blind, placebo-controlled, single and repeated dose escalation study to assess the safety, tolerability, pharmacokinetics and food effect of a new formulation of AUT00206 in healthy men and women

Next Previous
X
Search
Trial Profile

A randomised, double-blind, placebo-controlled, single and repeated dose escalation study to assess the safety, tolerability, pharmacokinetics and food effect of a new formulation of AUT00206 in healthy men and women

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 08 Dec 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AUT 00206 (Primary)
  • Indications Fragile X syndrome
  • Focus Pharmacokinetics
  • Sponsors Autifony Therapeutics

    • Most Recent Events

    • 14 Apr 2022 Status changed from recruiting to completed.
    • 21 Jan 2022 Recruitment completion is expected on 31Mar 2022, according to ISRCTN: Current Controlled Trials record.
    • 21 Jan 2022 Planned number of patients changed from 48 to 56.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top